H.C. Wainwright raised the firm’s price target on Fulcrum Therapeutics (FULC) to $25 from $18 and keeps a Buy rating on the shares after the company reported topline data from the PIONEER 20 mg cohort showing a “clear dose-response in patients while maintaining strong tolerability and encouraging VOC trends.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum announces results from 20 mg dose cohort of Phase 1b PIONEER trial
- Fulcrum Therapeutics initiated with a Buy at Truist
- Buy Rating for Fulcrum Therapeutics Driven by Promising PIONEER Study Results and Market Potential of Pociredir
- Fulcrum Therapeutics: Promising Sickle Cell Treatment with Pociredir Outshines Competitors
- Fulcrum’s pociredir shows promising early efficacy vs. mitapivat, says Leerink